Wegovy as a GLP-1 Agonist: the mechanism, the evidence, and your decision

What does 'GLP-1 agonist' actually mean for Wegovy?

GLP-1 stands for glucagon-like peptide-1. Your gut secretes it naturally after a meal, and its job is to signal fullness to the brain while slowing the rate at which food leaves the stomach. In people living with obesity, this signal is often blunted or short-lived. Semaglutide, the molecule in Wegovy, is a synthetic analogue of that hormone that works as a semaglutide agonist, it binds to the same receptors but stays active for much longer than the version your body produces.

The practical result: appetite falls, portion sizes tend to drop, and the pull toward snacking between meals weakens. Importantly, this is a single-receptor mechanism. Wegovy is not a dual agonist, it does not activate the GIP receptor the way tirzepatide does. That distinction matters when comparing options with a prescriber, because the receptor profile influences both the degree of weight loss seen in trials and the side-effect pattern.

The NHS semaglutide medicines page has a clear patient-level explanation of how semaglutide works and what to expect when starting treatment.

The decision most people are actually facing: is Wegovy the right fit?

If you've searched for information on Wegovy as a GLP-1 agonist, you're probably weighing it against at least one other option. The key variables are mechanism, evidence, dose flexibility and whether your medical history rules anything in or out.

On evidence alone, semaglutide's trial record is substantial. STEP 1 randomised over 1,900 adults and found roughly 15% average weight reduction at 2.4 mg over 68 weeks, a figure that shifted clinical thinking on what a medicine in this class could achieve. The newer 7.2 mg dose, approved by the MHRA in January 2026, pushes average losses toward 20%, closing some of the gap with tirzepatide at its highest licensed strength.

The other variable is lifestyle fit. Wegovy is a once-weekly subcutaneous injection. Some people find an injection easier to build into a weekly routine than a daily tablet, like setting a phone reminder the same morning every week. Others prefer the needle-free option now available with the oral Wegovy tablet. Neither preference is wrong; it is a genuine personal decision that a prescriber can help you think through. Our Wegovy overview page covers both the injection and tablet formats in full.

Eligibility and what single-receptor activation means for who Wegovy suits

Wegovy's UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes or dyslipidaemia. Lower thresholds apply for some ethnic backgrounds under UK guidance. A prescriber uses those criteria as a starting point, but your full medical history (current medicines, any history of pancreatitis, thyroid conditions, and more) shapes the final assessment. The criteria alone do not guarantee a prescription.

Because Wegovy acts on a single receptor pathway, it does not carry the same oral contraceptive absorption caution that applies to tirzepatide. That said, the MHRA advises using contraception during GLP-1 treatment generally, and discussing plans to conceive with your prescriber before starting. Pregnancy and breastfeeding are exclusions; the medicine is not licensed for under-18s. For a fuller picture of how semaglutide's receptor selectivity differs from other agents in the class, that page goes deeper into the pharmacology.

If you want a straightforward cost comparison before committing to a consultation, our Wegovy price comparison guide sets out what private treatment typically costs in the UK and what a legitimate price should include.

Side effects: the honest picture for a GLP-1 receptor agonist

GLP-1 receptor activation slows digestion, that is the mechanism behind the weight loss, and also behind most of the side effects. Nausea is the most commonly reported, followed by constipation, diarrhoea, burping and reflux. Fatigue and mild headache appear less frequently. Most people find these are worst in the first week or two after a dose increase and settle considerably after that.

Serious side effects are infrequent but worth knowing. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known risk with GLP-1 medicines: severe, persistent stomach pain that radiates to the back, with or without vomiting, needs urgent medical assessment. The MHRA's Yellow Card scheme lets patients report any suspected reactions directly. There is also a gallbladder signal worth discussing with a prescriber if you have a relevant history.

The side-effect profile is not a reason to avoid treatment if you are a suitable candidate, most people tolerate the dose escalation well, and our weight management overview covers what clinical support looks like throughout. A prescriber's job is to weigh all of this alongside your specific circumstances. If you'd like to speak to someone on our team, our clinical team page explains who reviews each consultation.